Drug Search Results
More Filters [+]

AE-04621

Alternative Names: ae-04621, ae04621, ae 04621
Latest Update: 2019-12-02
Latest Update Note: Clinical Trial Update

Product Description

Lu AE04621, a prodrug of catecholamine, was developed as a D1/D2agonist by Lundbecks neurodegeneration portfolio

Mechanisms of Action: DR Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Lundbeck
Company Location: DENMARK G7 00000
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AE-04621

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

16779A

P1

Completed

Parkinson's Disease

2016-12-01

Recent News Events

Date

Type

Title